Gut microbiota and tacrolimus dosing in kidney transplantation

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Lee, John R ^a,b   Muthukumar, Thangamani ^a,b   Dadhania, Darshana ^a,b   Taur, Ying ^a,c   Jenq, Robert R ^a,c   Toussaint, Nora C ^c,d   Ling, Lilan ^c   Pamer, Eric ^a,c   Suthanthiran, Manikkam ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NEW YORK GENOME CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CLOTRIMAZOLE; HEMOGLOBIN; MYCOPHENOLIC ACID; PREDNISONE; RNA 16S; TACROLIMUS;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG METABOLISM; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FEMALE; GENDER; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MICROBIAL DIVERSITY; PILOT STUDY; POLYMERASE CHAIN REACTION; POPULATION ABUNDANCE; RNA DEEP SEQUENCING; RNA SEQUENCE; STEROID THERAPY; THRUSH; AGED; BACTERIUM; DRUG EFFECTS; FECES; GENETICS; GRAFT REJECTION; MICROBIOLOGY; MIDDLE AGED;

BACTERIA (MICROORGANISMS); FAECALIBACTERIUM PRAUSNITZII;

ADULT; AGED; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RNA, RIBOSOMAL, 16S; TACROLIMUS; TRANSPLANT RECIPIENTS;

EID: 84928914705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122399     Document Type: Article

References (43)

1. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med. 1986;314(19):1219-25. PMID: 2871486
2. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014;14 Suppl 1:11-44. doi: 10.1111/ajt.12579 PMID: 24373166
3. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404-30. PMID: 8787947
4. Beermann KJ, Ellis MJ, Sudan DL, Harris MT. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. Clin Transplant. 2014;28(7):762-7. doi: 10.1111/ctr.12376 PMID: 24754564
5. Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70(6):685-93. PMID: 24658827
6. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948-57. doi: 10. 1111/j.1365-2125.2011.04039.x PMID: 21671989
7. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91(3):300-8. doi: 10.1097/TP.0b013e318200e991 PMID: 21206424
8. Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, et al. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol. 2011;67(8):787-95. doi: 10.1007/s00228-011-1010-y PMID: 21331500
9. Stratta P, Quaglia M, Cena T, Antoniotti R, Fenoglio R, Menegotto A, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol. 2012;68(5):671-80. doi: 10.1007/s00228-011-1150-0 PMID: 22101623
10. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18(11):2409-14. PMID: 14551375
11. Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19(48):9156-73. doi: 10.3748/wjg.v19.i48.9156 PMID: 24409044
12. Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IA. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol. 2013;76(3):425-31. doi: 10.1111/bcp. 12076 PMID: 23305195
13. Kang MJ, Kim HG, Kim JS, Oh Do G, Um YJ, Seo CS, et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol. 2013;9(10):1295-308. doi: 10.1517/17425255.2013.807798 PMID: 24033282
14. Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013;94(5):574-81. doi: 10.1038/clpt.2013.157 PMID: 23933971
15. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295-8. doi: 10.1126/science.1235872 PMID: 23869020
16. Haiser HJ, Turnbaugh PJ. Is it time for a metagenomic basis of therapeutics? Science. 2012;336(6086):1253-5. doi: 10.1126/science.1224396 PMID: 22674325
17. Nakamura A, Amada N, Haga I, Tokodai K, Kashiwadate T. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. Transplant Proc. 2014;46(2):592-4. doi: 10.1016/j.transproceed.2013.11.040 PMID: 24656020
18. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant. 2005;5(6):1383-91. PMID: 15888045
19. Sato K, Amada N, Sato T, Miura S, Ohashi Y, Sekiguchi S, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant. 2004;18(5):585-90. PMID: 15344965
20. Maes BD, Lemahieu W, Kuypers D, Evenepoel P, Coosemans W, Pirenne J, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant. 2002;2(10):989-92. PMID: 12484345
21. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant. 2005;9(3):315-23. PMID: 15910387
22. Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. Transplant Proc. 2010;42(5):1870-2. doi: 10.1016/j. transproceed.2010.02.095 PMID: 20620540
23. Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006;45(2):169-75. PMID: 16485913
24. Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005;39(6):1109-13. PMID: 15855244
25. Lee JR, Muthukumar T, Dadhania D, Toussaint NC, Ling L, Pamer E, et al. Gut microbial community structure and complications after kidney transplantation: a pilot study. Transplantation. 2014;98(7):697-705. doi: 10.1097/TP.0000000000000370 PMID: 25289916
26. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120(12):4332-41. doi: 10.1172/JCI43918 PMID: 21099116
27. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6(8):1621-4. doi: 10.1038/ismej.2012.8 PMID: 22402401
28. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: opensource, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537-41. doi: 10.1128/AEM.01541-09 PMID: 19801464
29. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 2007;35(21):7188-96. PMID: 17947321
30. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011;27(16):2194-200. doi: 10.1093/bioinformatics/btr381 PMID: 21700674
31. Huse SM, Welch DM, Morrison HG, Sogin ML. Ironing out the wrinkles in the rare biosphere through improved OTU clustering. Environ Microbiol. 2010;12(7):1889-98. doi: 10.1111/j.1462-2920.2010. 02193.x PMID: 20236171
32. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261-7. PMID: 17586664
33. Sheneman L, Evans J, Foster JA. Clearcut: a fast implementation of relaxed neighbor joining. Bioinformatics. 2006;22(22):2823-4. PMID: 16982706
34. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228-35. PMID: 16332807
35. Magurran AE. Biological diversity. Curr Biol. 2005;15(4):R116-8. PMID: 15723777
36. Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14. doi: 10.1038/nature11234 PMID: 22699609
37. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905-14. doi: 10.1093/cid/cis580 PMID: 22718773
38. Miquel S, Martin R, Rossi O, Bermudez-Humaran LG, Chatel JM, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255-61. doi: 10.1016/j.mib. 2013.06.003 PMID: 23831042
39. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012;3(4):289-306. PMID: 22572875
40. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519-28. doi: 10. 3748/wjg.v17.i12 PMID: 21472114
41. Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract. 2014;2014:872725. doi: 10.1155/2014/872725 PMID: 24799893
42. Tsunashima D, Kawamura A, Murakami M, Sawamoto T, Undre N, Brown M, et al. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. Clin Ther. 2014;36(5):748-59. doi: 10.1016/j.clinthera.2014.02.021 PMID: 24680768
43. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559-63. doi: 10.1038/nature12820 PMID: 24336217